Isopropyl-(6-methyl-5-nitro-pyridin-2-yl)-amine | 1246829-28-6

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: Isopropyl-(6-methyl-5-nitro-pyridin-2-yl)-amine
• 英文别名: 6-methyl-5-nitro-N-propan-2-ylpyridin-2-amine
• CAS: 1246829-28-6
• 化学式: C9H13N3O2
• 分子量: 195.22
• InChiKey: IFOPVANOAWECQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氯-2-甲基-3-硝基吡啶 、 异丙胺 以to give isopropyl-(6-methyl-5-nitro-pyridin-2-yl)-amine LCMS (m/z)的产率得到Isopropyl-(6-methyl-5-nitro-pyridin-2-yl)-amine
  参考文献：
  名称：

  Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof

  摘要：

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体并可用于治疗调节人类GLP-1受体有益的疾病、疾病或病状，例如2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及将这些化合物和组合物用于治疗这些有益的疾病、疾病或病状的用途。

  公开号：

  US20130096150A1

文献信息

• SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Mjalli Adnan M.M.

  公开号：US20110160198A1

  公开（公告）日：2011-06-30

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及替代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可用于治疗调节人类GLP-1受体有益的疾病、紊乱或病症，如2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在治疗调节人类GLP-1受体有益的这些疾病、紊乱或病症中的使用。
• Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
  申请人：Mjalli Adnan M. M.

  公开号：US08383644B2

  公开（公告）日：2013-02-26

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可在治疗调节人类GLP-1受体有益的疾病、疾病、或病情，如2型糖尿病。本发明还涉及包含这些化合物的制药组合物，以及在治疗这些有益的疾病、疾病或病情中使用这些化合物和组合物。
• Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof
  申请人：TransTech Pharma, Inc

  公开号：US20130096150A1

  公开（公告）日：2013-04-18

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体并可用于治疗调节人类GLP-1受体有益的疾病、疾病或病状，例如2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及将这些化合物和组合物用于治疗这些有益的疾病、疾病或病状的用途。
• Substituted azoanthracene derivatives and intermediates for preparation thereof
  申请人：TransTech Pharma, LLC

  公开号：US09175003B2

  公开（公告）日：2015-11-03

  The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.

  本发明涉及取代的偶氮蒽衍生物及其制备中间体。这些取代的偶氮蒽衍生物和相关的中间体可用于制备药物组合物，用于治疗或预防调节人类GLP-1受体有益的疾病、疾病和状况。
• US8383644B2
  申请人：——

  公开号：US8383644B2

  公开（公告）日：2013-02-26